Iclusig 45mg Tablet (Ponatinib)

Iclusig 45mg Tablet is a target therapy-based allopathic medication which is used to treat various phases of Chronic Myeloid Leukemia (CML) as well as Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). It has an active ingredient known as ponatinib that belongs to the class of medications called tyrosine kinase inhibitors. Ponatinib 45mg Tablet (Iclusig) blocks the abnormal BCR-ABL protein, including forms with the T315I mutation, as it is responsible for cancer cell growth and proliferation. Thus, this binds to the mutated BCR-ABL tyrosine kinase that inhibits further signaling of cancer progression. As a result, the cancer cell eventually dies.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed as whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. A Ponatinib 45mg tablet is given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include skin rash, dry skin, abdominal pain, constipation, diarrhea, nausea, headache, tiredness, joint or muscle pain, and changes in blood counts. A few patients can undergo severe side effects, including heart attack, stroke, severe hypertension, liver toxicity, pancreatitis and heart failure. Most of the Ponatinib 45mg Tablet side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine can cause fetal harm and should not be used during pregnancy. Women who can become pregnant should use effective contraception during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Ponatinib 45mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Iclusig 45mg Tablet is an allopathic targeted medication that can only be purchased with a prescription. Like any other chemical-based drug, its chemical-based formula causes multiple negative effects. See your physician if these side effects persist for an extended period of time.

Common side effects of the Iclusig 45mg tablet (ponatinib 45mg) are:
● Fever
● Constipation
● Rashes
● Weight Loss
● Abdominal Pain
● Anemia
● Hypertension
● Febrile Neutropenia

Serious side effects

​● Myocardial Infarction
● Cardiac Failure
● Acute Kidney Injury
● Pancreatitis

The standard recommended starting dosage of Iclusig 45mg Tablet (ponatinib 45mg) is 45mg for chronic myeloid leukaemia (CML), whereas 30mg is recommended for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) that can be reduced to even 15mg later on. This medicine is taken orally as whole, without breaking, biting or chewing. Consult your doctor for the exact dosage that is especially meant for you.

● Shamroe, C. L., & Comeau, J. M. (2013). Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. Annals of Pharmacotherapy, 47(11), 1540-1546.

● Poch Martell, M., Sibai, H., Deotare, U., & Lipton, J. H. (2016). Ponatinib in the therapy of chronic myeloid leukemia. Expert review of hematology, 9(10), 923-932.

● Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., ... & Talpaz, M. (2012). Ponatinib in refractory Philadelphia chromosome–positive leukemias. New England Journal of Medicine, 367(22), 2075-2088.

● Othman, T., Ngo, D., Tinajero, J., & Aldoss, I. (2025). Ponatinib in the treatment of acute lymphoblastic leukemia. Future Oncology, 1-9.